MedTrace Logo

Pharmacokinetics Of Celecoxib Test Formulations

NCT00925106 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-02-02

No results posted yet for this study

Summary

The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Celebrex capsule

Single dose 200 mg commercial Celebrex capsule

DRUG

Test formulation D1

Single dose 150 mg celecoxib as formulation D1

DRUG

Test formulation D2

Single dose 150 mg celecoxib as formulation D2

DRUG

Test formulation D3

Single dose 150 mg celecoxib as formulation D3

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00925106 on ClinicalTrials.gov